Related Experiment Video
Updated: Apr 18, 2026
09:12
Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
Published on: May 11, 2018
7.4K
Thiol-derivatized minihepcidins retain biological activity.
Eileen Fung1, Kristine Chua1, Tomas Ganz1
1Department of Medicine, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.
Bioorganic & Medicinal Chemistry Letters
|January 21, 2015
Summary
Researchers developed S-protected minihepcidins, which mimic the iron-regulating hormone hepcidin. These novel compounds maintain bioactivity while reducing potential side effects associated with free thiols, paving the way for improved hepcidin agonists.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Pharmacology
Background:
- Minihepcidins are peptide analogs of hepcidin, an iron-regulatory hormone.
- The free thiol group at cysteine residue 7 is vital for minihepcidin bioactivity but poses pharmaceutical challenges due to reactivity and potential side effects.
- Reactivity of the free thiol can lead to various undesirable derivatives, impacting drug stability and safety.
Purpose of the Study:
- To develop S-protected minihepcidin analogs that retain bioactivity.
- To mitigate the reactivity and potential side effects of the free thiol group in minihepcidins.
- To explore the therapeutic potential of stabilized minihepcidin derivatives as hepcidin agonists.
Main Methods:
- Synthesis of novel S-protected minihepcidin analogs using activated vinyl thioethers.
- In vitro testing of synthesized analogs to assess their bioactivity compared to the parental minihepcidin PR73.
- In vivo evaluation of the most active S-protected analog (PR73SH) to determine its efficacy and safety profile.
Main Results:
- Novel S-protected minihepcidin analogs were successfully synthesized.
- In vitro studies demonstrated that the S-protected analogs exhibited bioactivity comparable to the parent molecule, PR73.
- In vivo testing of the lead compound, PR73SH, revealed an activity profile analogous to PR73, indicating preserved physiological function.
Conclusions:
- S-vinyl-derivatization is a viable strategy for protecting the thiol group in minihepcidins.
- This protection strategy effectively maintains the bioactivity of minihepcidins.
- S-protected minihepcidins represent a promising avenue for developing safer and more stable hepcidin agonists for therapeutic applications.
